344P - TERT as a prognostic factor for gliomas progression-free survival (PFS)

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Central Nervous System Malignancies
Presenter Maria Pilar Solis Hernandez
Citation Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367
Authors M.P. Solis Hernandez1, L. Faez1, D. Cantero2, A. Hernandez Lain2, P. Sanchez Gomez2, Y. Ruano2, M.D.M. Galera3, J.M. Sepúlveda Sánchez3
  • 1Medical Oncology, Hospital Universitario Central de Asturias, 33011 - Oviedo/ES
  • 2Multidisciplinar Neurooncology Unit, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 3Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES

Abstract

Background

High frequencies of TERT promoter mutations have been described in gliomas. This underlies telomere maintenance upregulating telomerases. The mutation rate is higher in glioblastomas (GBM).

Methods

Observational and retrospective analysis of 100 patients with different histological types of gliomas. TERT mutations were determined by RT-PCR in brain tumor samples obtained from paraffin-embedded tissue. Survival analysis was performed with Kaplan-Meier curves compared by Log-Rank test.

Results

There were included 52% GBM, oligodendrogliomas (OO) 12% and astrocytomas (AA) 29% each, and oligoastrocytomas (OA) 7%. The highest rate of TERT mutation was achieved in the OO group (66.7%) followed by GBM (55.8%) and AA (27.6%). From the 46% patients with TERT mutation: GBM 63%, OO and AA each 17.4%. Median relapse/progression free survival was 37, 33 and 7 months for AA, OO, OA and GBM respectively if wild type TERT, while if mutated 14, 20 and 8 months. TERT and ATRX seem to be mutually exclusive as there were only 2% coincidences.

Wild type TERT Mutated TERT
Median PFS Range Median PFS Range
Astrocytoma 37.6 124 14.2 120
Glioblastoma 7.1 37 8.8 42
Oligoastrocytoma 19.3 73 82.7 0
Oligodendroglioma 33.1 34 20.7 98

Conclusions

TERT mutations are determinant prognostic factors in glioma biology of both high and low grade.

Clinical trial identification

Legal entity responsible for the study

Hospital Universitario 12 de Octubre: Multidisciplinar Neurooncology Unit

Funding

Hospital Universitario 12 de Octubre: Multidisciplinar Neurooncology Unit

Disclosure

All authors have declared no conflicts of interest.